Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment

Assunta Bianco; Agata Katia Patanella; Viviana Nociti; Chiara De Fino; Matteo Lucchini; Francesco Lo Savio; Paolo Maria Rossini; Massimiliano Mirabella

doi:10.1016/j.msard.2016.06.005

Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment

Assunta Bianco^*, Agata Katia Patanella, Viviana Nociti, Chiara De Fino, Matteo Lucchini, Francesco Lo Savio, Paolo Maria Rossini, Massimiliano Mirabella

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo in rivista

3 Citazioni (Scopus)

Abstract

In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.

Lingua originale	English
pagine (da-a)	11-13
Numero di pagine	3
Rivista	Multiple Sclerosis and Related Disorders
Volume	9
DOI	https://doi.org/10.1016/j.msard.2016.06.005
Stato di pubblicazione	Pubblicato - 2016

Keywords

Adverse event
Fingolimod
Multiple sclerosis
Neurology
Neurology (clinical)
Respiratory
Side effect

Accesso al documento

10.1016/j.msard.2016.06.005

Altri file e collegamenti

Cita questo

@article{e380ec0ebd0b48d4b647756491d86a32,

title = "Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment",

abstract = "In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.",

keywords = "Adverse event, Fingolimod, Multiple sclerosis, Neurology, Neurology (clinical), Respiratory, Side effect, Adverse event, Fingolimod, Multiple sclerosis, Neurology, Neurology (clinical), Respiratory, Side effect",

author = "Assunta Bianco and Patanella, {Agata Katia} and Viviana Nociti and {De Fino}, Chiara and Matteo Lucchini and Savio, {Francesco Lo} and Rossini, {Paolo Maria} and Massimiliano Mirabella",

year = "2016",

doi = "10.1016/j.msard.2016.06.005",

language = "English",

volume = "9",

pages = "11--13",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment

AU - Bianco, Assunta

AU - Patanella, Agata Katia

AU - Nociti, Viviana

AU - De Fino, Chiara

AU - Lucchini, Matteo

AU - Savio, Francesco Lo

AU - Rossini, Paolo Maria

AU - Mirabella, Massimiliano

PY - 2016

Y1 - 2016

N2 - In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.

AB - In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.

KW - Adverse event

KW - Fingolimod

KW - Multiple sclerosis

KW - Neurology

KW - Neurology (clinical)

KW - Respiratory

KW - Side effect

KW - Adverse event

KW - Fingolimod

KW - Multiple sclerosis

KW - Neurology

KW - Neurology (clinical)

KW - Respiratory

KW - Side effect

UR - http://hdl.handle.net/10807/92664

UR - http://www.elsevier.com/wps/find/journaldescription.cws_home/725776/description#description

U2 - 10.1016/j.msard.2016.06.005

DO - 10.1016/j.msard.2016.06.005

M3 - Article

SN - 2211-0348

VL - 9

SP - 11

EP - 13

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

ER -

Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo